{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:49:28Z","timestamp":1774626568182,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Uppsala County Association against Heart and Lung Disease"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"The Medicines Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Momenta"},{"name":"Regado"},{"DOI":"10.13039\/100004339","name":"Sanofi Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Accumetrics"},{"name":"Dynabyte"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>We evaluated the predictive ability of cystatin C and creatinine-based estimations of glomerular filtration rate (eGFR), including the Chronic Kidney Disease\u2013Epidemiology (CKD-EPI) equation, in acute coronary syndrome (ACS) patients with (STE-ACS) or without (NSTE-ACS) ST elevation in a large contemporary ACS population.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Concentrations of cystatin C and creatinine, as well as eGFR at randomization, were measured in 16 401 patients in the Platelet Inhibition and Patient Outcomes (PLATO) study and evaluated as predictors of the composite end point of cardiovascular death or myocardial infarction within 1 year. Two Cox proportional hazards models were used, the first adjusting for clinical characteristics and the second for clinical characteristics plus the biomarkers N-terminal pro\u2013B-type natriuretic peptide, troponin I, and C-reactive protein.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The median cystatin C value was 0.83 mg\/L. Increasing quartiles of cystatin C were strongly associated with poor outcome (6.9%, 7.1%, 9.5%, and 16.2%). The fully adjusted hazard ratios per SD of cystatin C in the NSTE-ACS and STE-ACS populations were 1.12 (95% CI 1.04\u20131.20) (n = 8053) and 1.06 (95% CI 0.97\u20131.17) (n = 5278), respectively. There was no significant relationship of cystatin C with type of ACS (STE or NSTE). c Statistics ranged from 0.6923 (cystatin C) to 0.6941 (CKD-EPI).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Cystatin C concentration contributes independently in predicting the risk of cardiovascular death or myocardial infarction in NSTE-ACS, with no interaction by type of ACS. CKD-EPI exhibited the largest predictive value of all renal markers. Nevertheless, the additive predictive value of cystatin C or creatinine-based eGFR measures in the unselected ACS patient is small.<\/jats:p><\/jats:sec>","DOI":"10.1373\/clinchem.2011.171520","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T14:41:44Z","timestamp":1322750504000},"page":"190-199","source":"Crossref","is-referenced-by-count":36,"title":["Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non\u2013ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study"],"prefix":"10.1093","volume":"58","author":[{"given":"Axel","family":"\u00c5kerblom","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and"},{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Wallentin","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and"},{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agneta","family":"Siegbahn","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Center of Excellence - Inflammation, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C","family":"Becker","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Budaj","sequence":"first","affiliation":[{"name":"Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Buck","sequence":"first","affiliation":[{"name":"AstraZeneca Research and Development, Wilmington, DE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Giannitsis","sequence":"first","affiliation":[{"name":"Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Horrow","sequence":"first","affiliation":[{"name":"AstraZeneca Research and Development, Wilmington, DE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Husted","sequence":"first","affiliation":[{"name":"Department of Cardiology, \u212brhus University Hospital, \u212brhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo A","family":"Katus","sequence":"first","affiliation":[{"name":"Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"first","affiliation":[{"name":"NSERM U-698, Assistance Publique-H\u00f4pitaux de Paris and Universit\u00e9 Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F","family":"Storey","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Science, University of Sheffield, Sheffield, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"\u00c5senblad","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and"},{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan K","family":"James","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and"},{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,1,1]]},"reference":[{"key":"2020022705132323000_B1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2423(01)35015-1","article-title":"Cystatin C: properties and use as diagnostic marker","volume":"35","author":"Grubb","year":"2000","journal-title":"Adv Clin Chem"},{"key":"2020022705132323000_B2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1042\/bj2680287","article-title":"Structure and expression of the human cystatin C gene","volume":"268","author":"Abrahamson","year":"1990","journal-title":"Biochem J"},{"key":"2020022705132323000_B3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/clinchem\/48.5.699","article-title":"Cystatin C: an improved estimator of glomerular filtration rate?","volume":"48","author":"Laterza","year":"2002","journal-title":"Clin Chem"},{"key":"2020022705132323000_B4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int"},{"key":"2020022705132323000_B5","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"2020022705132323000_B6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2020022705132323000_B7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1373\/clinchem.2009.128397","article-title":"Cystatin C and cardiovascular risk","volume":"55","author":"Taglieri","year":"2009","journal-title":"Clin Chem"},{"key":"2020022705132323000_B8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2020022705132323000_B9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2020022705132323000_B10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2020022705132323000_B11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.V133745","article-title":"Renal insufficiency and subsequent death resulting from cardiovascular disease in the united states","volume":"13","author":"Muntner","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2020022705132323000_B12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"2020022705132323000_B13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ahj.2010.03.028","article-title":"Cockcroft-Gault is better than the Modification of Diet in Renal Disease study formula at predicting outcome after a myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)","volume":"159","author":"Szummer","year":"2010","journal-title":"Am Heart J"},{"key":"2020022705132323000_B14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"2020022705132323000_B15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1161\/01.CIR.0000145166.44942.E0","article-title":"Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome","volume":"110","author":"Jernberg","year":"2004","journal-title":"Circulation"},{"key":"2020022705132323000_B16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1373\/clinchem.2008.119669","article-title":"Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T","volume":"55","author":"Windhausen","year":"2009","journal-title":"Clin Chem"},{"key":"2020022705132323000_B17","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa043161","article-title":"Cystatin C and the risk of death and cardiovascular events among elderly persons","volume":"352","author":"Shlipak","year":"2005","journal-title":"N Engl J Med"},{"key":"2020022705132323000_B18","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1253\/circj.CJ-08-0943","article-title":"Prognostic significance of cystatin C in patients with ST-elevation myocardial infarction","volume":"73","author":"Ichimoto","year":"2009","journal-title":"Circ J"},{"key":"2020022705132323000_B19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral p2y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am Heart J"},{"key":"2020022705132323000_B20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2020022705132323000_B21","unstructured":"Gentian. www.gentian.no (accessed November 2011)."},{"key":"2020022705132323000_B22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"2020022705132323000_B23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2020022705132323000_B24","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jacc.2007.11.045","article-title":"Cockcroft-Gault versus Modification of Diet in Renal Disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes","volume":"51","author":"Melloni","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2020022705132323000_B25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/eurheartj\/ehn598","article-title":"Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Atherogene study","volume":"30","author":"Keller","year":"2009","journal-title":"Eur Heart J"},{"key":"2020022705132323000_B26","unstructured":"Food and Drug Administration. http:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/guidances2010 (Accessed November 2011)."}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/1\/190\/32657601\/clinchem0190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/1\/190\/32657601\/clinchem0190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T06:42:41Z","timestamp":1639809761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/58\/1\/190\/5620557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,1]]},"published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2011.171520","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,1,1]]},"published":{"date-parts":[[2012,1,1]]}}}